quinta-feira, dezembro 23, 2004
FDA aprova nova formulação do Invirase
The U.S. Food and Drug Administration (FDA) has granted approval to a more potent formulation of Roche AG's HIV drug Invirase (saquinavir), meaning that patients will not need to take as many of the pills.
The FDA approved the drug in a 500-mg formulation, cutting the daily pill requirement from 5 to 2, Roche said in a statement on Monday.
Invirase, which is not among the Swiss drugmaker's top 20 products, was launched in 1995 and was the first HIV protease inhibitor on the market.